Tweet
is there some strategy to follow
-
-
There is no rigorous defined method for selecting an outgroup. You obviously want something that is not part of your ingroup but is not so distantly related that inferred homology is difficult or practically impossible.
As to the first criterion, that depends entirely on what your ingroup actually is and the diversity it already covers.
So one way to pick an outgroup for sequence data would be to build a tree with just your ingroup sequences. Take your most divergent branch from that, and do a BLAST search to find something that clearly is not part of your ingroup sequence family, but still retains some evidence of clear homology to them.
Or, if you are inferring an organismal tree, you can just do a literature search for a potential common ancestor to your ingroup, and then pull a sequence for a member of that taxon from available databases.Michael Black, Ph.D.
ScitoVation LLC. RTP, N.C.
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment